Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01833078 · ClinicalTrials.gov registry record · Phase 2
Ghrelin Repeated Dose Study
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01833078: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT01833078 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01833078, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Frailty is a geriatric syndrome leading to physical deterioration including muscle wasting (sarcopenia) and unintentional weight loss. There are currently no approved therapies for frailty. Ghrelin is a hormone produced by the stomach that stimulates appetite centers in the brain. The investigators already know that a single dose of Ghrelin improves food intake immediately after the dose in frail older people. In this study, the investigators are trying to find out if repeated daily doses of ghrelin will help frail older people improve food intake for multiple days in a row.
Interventions
- DRUG ghrelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01833078
The ClinicalTrials.gov registry entry for NCT01833078 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ghrelin is the first listed.
NCT01833078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01833078 about?
NCT01833078 is a clinical study titled "Ghrelin Repeated Dose Study". Frailty is a geriatric syndrome leading to physical deterioration including muscle wasting (sarcopenia) and unintentional weight loss. There are currently no approved therapies for frailty. Ghrelin is a hormone produced by the stomach that stimulates appetite centers in the brain. The investigators ...
What is the current status of trial NCT01833078?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2013-02. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01833078?
The interventions under investigation include: ghrelin (DRUG).
Who is sponsoring clinical trial NCT01833078?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.